BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 26729441)

  • 21. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
    Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
    Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
    Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
    J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
    Vaughn DJ
    Urol Clin North Am; 2007 May; 34(2):171-7; abstract viii-ix. PubMed ID: 17484922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
    Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
    Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
    J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
    Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
    Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG).
    Malogolowkin MH; Krailo M; Marina N; Olson T; Frazier AL
    Pediatr Blood Cancer; 2013 Oct; 60(10):1602-5. PubMed ID: 23703725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
    Bosl GJ; Geller NL; Vogelzang NJ; Carey R; Auman J; Whitmore WF; Herr H; Morse M; Sogani P; Chan E
    J Clin Oncol; 1987 Mar; 5(3):436-40. PubMed ID: 2434627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cooperative therapy study of nontesticular germ cell tumors MAKEI 83 of the Society of Pediatric Oncology: analysis after 3 years].
    Göbel U; Gutjahr P; Jürgens H; Kabisch H; Lampert F; Spaar HJ; Sternschulte W; Harms D
    Klin Padiatr; 1986; 198(3):237-44. PubMed ID: 2425122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
    Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non-testicular germ cell tumors: analysis of the therapy study MAKEI 83/86 anc changes in the protocol for the follow-up study].
    Göbel U; Bamberg M; Haas RJ; Bökkerink JP; Brämswig G; Calaminus G; Engert J; Gadner H; Havers W; Janka-Schaub GE
    Klin Padiatr; 1989; 201(4):247-60. PubMed ID: 2476583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide in testicular cancer: the Indiana University experience.
    Loehrer PJ; Williams SD; Einhorn LH
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):96-101. PubMed ID: 2539649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Result of treatment for advanced germ cell tumor in the last decade].
    Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
    Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882).
    Rescorla F; Billmire D; Stolar C; Vinocur C; Colombani P; Cullen J; Giller R; Cushing B; Lauer S; Davis M; Hawkins E; Shuster J; Krailo M
    J Pediatr Surg; 2001 Jan; 36(1):12-7. PubMed ID: 11150431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.